RANK‐Fc and denosumab decreased tumor cell proliferation and attenuated tumor growth in the STG139‐M model, suggesting that the anti‐proliferative effects were mainly due to inhibition of tumor RANKL (Figs 2F and EV4B and C), in line with (Gonzalez‐Suarez et al, 2010). The gene discussed is TNFRSF11A; the disease is neoplasm.